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Abstract
Introduction: Depression is a highly prevalent condition in the elderly, with a vast impact on quality of life, life
expectancy, and medical outcomes. Selective serotonin reuptake inhibitors (SSRIs) are the most commonly
prescribed agents in this condition and, although generally safe, tolerability issues cannot be overlooked.
Vortioxetine is an antidepressant with a novel mechanism of action. Based on studies to date, it may have a
promising tolerability profile in the elderly, as it does not adversely affect psychomotor or cognitive performance
and does not alter cardiovascular and endocrine parameters. The present study aims to assess the tolerability profile
of vortioxetine in comparison with the SSRIs considered as a single group in elderly participants with depression.
The rate of participants withdrawing from treatment due to adverse events after 6 months of follow up will be the
primary outcome.
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Methods and analysis: This is a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial
funded by the Italian Medicines Agency (AIFA - Agenzia Italiana del Farmaco). Thirteen Italian Community Psychiatric
Services will consecutively enrol elderly participants suffering from an episode of major depression over a period of
12 months. Participants will be assessed at baseline and after 1, 3 and 6 months of follow up. At each time point,
the following validated rating scales will be administered: Montgomery–Åsberg Depression Rating Scale (MADRS),
Antidepressant Side-Effect Checklist (ASEC), EuroQual 5 Dimensions (EQ-5D), Short Blessed Test (SBT), and Charlson
Age-Comorbidity Index (CACI). Outcome assessors and the statistician will be masked to treatment allocation. A
total of 358 participants (179 in each group) will be enrolled.
Ethics and dissemination: This study will fully adhere to the ICH E6 Guideline for Good Clinical Practice.
Participants’ data will be managed and safeguarded according to the European Data Protection Regulation 2016/
679. An external Ethical Advisory Board will help guarantee high ethical standards.
Trial registration: Clinicaltrials.gov: NCT03779789, Registered on 19 December 2018. Submitted on 19 December.
EudraCT number: 2018–001444-66.
Trial status: Protocol version 1.5; 09/06/2018. Recruitment started In February 2019 and it is ongoing. It is expected
to end approximately on 30 September 2021.
Keywords: Randomized clinical trial, Pragmatic trial, Elderly, Antidepressants, Vortioxetine, Depression
Introduction
Background and rationale
Depression is among the most disabling conditions
worldwide [1]. It occurs in about 4% of older people in
the community [2] and in up to 49% of persons admitted
to nursing homes and hospitals [3, 4]. In older people,
depression is associated with poor quality of life, reduced
life expectancy, high risk of suicide [5], cognitive decline
and dementia [6], reduced adherence to medical treat-
ments and, therefore, poorer medical outcomes [7].
Current guidelines recommend pharmacological treat-
ment in the case of moderate-to-severe depression [8].
Although different medications can be used in people
with depression, the first-line treatment is typically
antidepressants. Traditionally, the theory of a “chemical
imbalance” (and particularly reduction in serotonin
levels in some areas of the central nervous system) was
claimed to explain the pharmacological mechanism of
these drugs. However, there is growing evidence on
multiple therapeutic targets of antidepressants, including
neurotrophic actions and modulation of genetic, immun-
ity and inflammatory processes. Selective serotonin re-
uptake inhibitors (SSRIs) are a class of antidepressants
with the simplest pharmacological profile, and are gener-
ally chosen as a first-line treatment and are considered
to represent a good balance between efficacy and safety
in the general population, according to data from
randomized trials [9]. However, in older people there is
debate around the benefits and harms of antidepressants.
Older people may be particularly vulnerable to adverse
events due to frailties associated with the ageing process
[10], medical comorbidities, multiple treatments and
high risk of pharmacological interactions [11, 12]. SSRIs
are generally considered the safest option in older people
[13] and are therefore recommended by most guidelines
as first-choice treatment [8, 14]. However, SSRIs are not
without risks in older people; in particular, hyponatrae-
mia, postural hypotension, falls, gastrointestinal bleeding
and sexual dysfunctions are the most common side
effects [15, 16]. Other antidepressants, such as tricyclic
antidepressants (TCAs), serotonin and norepinephrine
reuptake inhibitors (SNRIs) and mirtazapine are associ-
ated with a similar or higher risk of a number of adverse
events, including sedation, confusion, urinary retention
and cardiovascular and gastrointestinal issues [16], and
are generally avoided in these patients. Moreover, the
magnitude of beneficial effects of antidepressants in late-
life depression has been questioned [17], making it hard
for clinicians to accurately balance benefits and risks.
Vortioxetine is a novel antidepressant, licensed for the
treatment of depression in 2013 by the US Food and
Drug Administration (FDA) and the European Medi-
cines Agency (EMA) [18, 19]. Vortioxetine is an antag-
onist to 5-HT3, 5-HT1D and 5-HT7 receptors, a partial
agonist to the 5-HT1B receptor and a 5-HT1A receptor
agonist [20, 21]. Its mechanism of action is not yet fully
understood, but it is likely to be related both to direct
modulation of the serotoninergic receptor activity and to
inhibition of the serotonin transporter. Despite similar-
ities with SSRIs, its pharmacological profile is claimed to
be novel, particularly because of its stronger binding to
the 5-HT1B receptor as compared to other SSRIs [22],
and because of promising results in animal models,
showing antipsychotic, antidepressant, and pro-cognitive
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activities (enhanced memory, cognition and executive
functions) [23]. It is classified among “other antidepres-
sants” by the World Health Organization (WHO) ATC/
DDD Index 2018 [24]. Vortioxetine has similar pharma-
cokinetic properties in young and older adults [18], and
current data suggest it should not adversely affect
psychomotor or cognitive performance, wakefulness,
body weight or electrocardiogram parameters [25, 26].
Further, possible beneficial effects on cognition emerged
from three randomized trials in participants with cogni-
tive impairment [27]. A recent Cochrane systematic
review, which included 15 randomized trials (7746 par-
ticipants), showed vortioxetine to be effective compared
to placebo, while no significant differences emerged be-
tween vortioxetine and SNRIs as a class, in terms of both
efficacy and tolerability [28]. The review did not include
any study comparing vortioxetine with the SSRIs, but a
recent network meta-analysis showed that vortioxetine is
well-tolerated and effective when indirectly compared to
SSRIs [9, 29]. Moreover, in two recent randomized trials,
vortioxetine did not show significantly different effects
on mood or cognitive performance when compared to
paroxetine [30] and escitalopram [31], respectively. The
only available trial conducted in the older people
demonstrated that vortioxetine was more effective than
placebo in terms of response, i.e. participants with > =
50% reduction in the Hamilton Depression Scale-24 total
score in 8 weeks (301 participants, relative risk 1.49, 95%
CI 1.14 to 1.95), while no differences emerged in terms
of tolerability [32].
Objectives
The study will assess if, under real-world clinical cir-
cumstances, vortioxetine is better-tolerated as compared
with the SSRIs considered as a group in elderly partici-
pants with depression. In addition to tolerability, as
secondary outcomes the study will assess acceptability,
overall mortality, self-harm and suicide, adverse events,
improvement of depressive symptoms, quality of life and
cognitive performance.
Methods and analysis
This protocol has been reported according to the Stand-
ard protocol items: recommendation for interventional
trials (SPIRIT) statement requirements. The complete
SPIRIT checklist is available in Additional file 1 and in
the table at the end of the manuscript (Fig. 1).
Trial design
The Vortioxetine in the elderly vs SSRIs: a pragmatic
assessment (VESPA) study is a randomized, parallel-
group, multicentre, open-label, pragmatic, superiority trial.
Over a 12-month recruitment period, psychiatrists from
13 Italian Psychiatric Services will consecutively enrol
inpatients and outpatients aged 65 or years or older suffer-
ing from an episode of major depression and requiring
treatment with an antidepressant. A threshold of 65 years
of age was selected because this is generally accepted as
the point of transition into older age [33] and has broadly
been accepted as standard in previous randomized trials
[29]. The study was designed in accordance with the prin-
ciples of pragmatism, which aim to assess interventions
under real-life circumstances by recruiting participants in
ordinary care settings and employing outcomes with high
practical value for clinicians [34].
Participants will be randomly allocated to vortioxetine
or to one of the SSRIs. Apart from treatment allocation,
clinicians and participants will be free to increase or
decrease the dose according to clinical status and
circumstances, and to stop or continue treatment as
clinically indicated. Similarly, the use of concomitant
medications during the study will be allowed according
to clinical status and circumstances. Routine care out-
side the trial will continue as usual. Participants will be
seen as often as clinically indicated during the study,
with no extra visits required for the trial. The only re-
quirement will be follow-up visits at 1, 3 and 6 months
of follow up (Fig. 2). Visits will be conducted at the usual
care facilities in each centre.
As a consequence of these pragmatic characteristics
oriented to resemble clinical practice as much as
possible, both participants and clinicians will not be
blind to pharmacological treatments provided during the
trial. Blinding will be applied to outcome assessors and
statisticians performing the analyses. The study has been
designed according to the principles described in the
Consolidated standards of reporting trials (CONSORT)
statement (extended version for pragmatic trials) [35]
and in agreement with the SPIRIT 2013 statement [36]
(see Additional file 1). The study is financially supported
by the Italian Medicines Agency (AIFA - Agenzia
Italiana del Farmaco) and has been approved by the
Ethics Committee for Clinical Research of Verona and
Rovigo (Comitato Etico per la Sperimentazione Clinica
delle Province di Verona e Rovigo) (prot. n. 61,211 of the
19/09/2018; Protocol version n. 1.5 of the 09/06/2018).
Assessment of pragmatism
To quantify the level of pragmatism of our study, we
employed the Pragmatic–Explanatory Continuum Indicator
Summary-2 (PRECIS-2) [37]. This is a validated tool, devel-
oped to help investigators make design decisions consistent
with the intended purpose of their trial. It explores nine do-
mains (eligibility criteria, recruitment, setting, organisation,
flexibility (delivery), flexibility (adherence), follow up, pri-
mary outcome and primary analysis), for each of which a
score from 1 (very explanatory) to 5 (very pragmatic) is
provided. The result is graphically summarized in Fig. 3.
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Reasons for the scoring are reported in Table 1.
Routine use of the PRECIS-2 tool when submitting
randomized controlled trial (RCT) protocols to funders,
research ethics committees and peer-reviewed journals,
has increasingly been recommended, considering that
not all RCTs self-labelled as “pragmatic” or “naturalistic”
are actually pragmatic. This process can also help us
understand the extent to which trial results may be
relevant to real-world practice [38].
Eligibility criteria and study setting
The following inclusion criteria will be applied:
a. The participant is 65 years of age or older;
b. The participant is willing to participate by signing
an informed consent form;
c. The participant is suffering from an episode of
major depression, according to the clinical
judgment of recruiting psychiatrists, considering the
FIg. 1 SPIRIT figure
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Fig. 3 Pragmatism wheel according to the Pragmatic–explanatory continuum indicator summary-2 (PRECIS-2) tool
Fig. 2 Study flow-chart. SSRI, selective serotonin reuptake inhibitor
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Diagnostic and statistical manual of mental
disorders, 5th edition (DSM-5) criteria as a reference
standard;
d. Treatment with an antidepressant is appropriate,
based on clinical judgment;
e. In case the participant is receiving
pharmacological treatment, there is clinical
agreement between investigator and participant
to discontinue any of the following concomitant
drugs: antidepressant, second generation
antipsychotic or lithium. All other concomitant
medications are allowed;
f. Uncertainty about which trial treatment would be
best for the participant.
Participants will be excluded in the case of:
a. Dementia, of any type and stage, as formally
diagnosed by a specialist (geriatrician, neurologist or
other);
b. Diagnosis of schizophrenia or bipolar disorder;
c. Clinical conditions or treatments that
contraindicate the use of oral vortioxetine or
SSRIs, according to clinical/medical judgement
(for example conditions or treatments that
increase risk of bleeding, seizures, serotoninergic
syndrome, hyponatraemia, etc.).
All medications will be prescribed according to routine
clinical practice and current guidelines [8, 14], in compli-
ance with the summary of product characteristics (SPC)
registered in the AIFA databank (https://farmaci.agenzia-
farmaco.gov.it/bancadatifarmaci/home). Patients with a
current depressive episode already receiving an anti-
depressant treatment that proved to be ineffective and/or
poorly tolerated, and could benefit from the switch to
vortioxetine or an SSRI, will be eligible for the study.
No exclusion criteria will be applied in terms of setting
of recruitment, severity of depression, past use of psycho-
tropic drugs, current use of benzodiazepines (as long as
SPC indications are respected), number and severity of
medical comorbidities and multiple pharmacotherapies.
Table 1 Scoring using the PRECIS-2 tool
Items Score Rationale
Eligibility - to what extent are the participants in the trial similar to
those who would receive this intervention if it was part of usual care
4 Target population: elderly with depression. Inclusion criteria are wide.
No exclusion criteria will be applied in terms of setting of recruitment,
severity of depression, past use of psychotropic drugs, current use of
benzodiazepines, number and severity of medical comorbidities and
multiple pharmacotherapies. Diagnoses are based on clinical judgment
(considering DSM-5 criteria as a reference), as it is in usual practice
Recruitment - how much extra effort is made to recruit participants
over and above what that would be used in the usual care setting to
engage with patients?
5 Participants will be recruited without extra efforts. They will be
recruited during usual appointments and/or visits
Setting - how different is the setting of the trial and the usual care
setting?
4 The study is multicentre, based in more than 10 psychiatric centres of
the National Health System in Italy with a University centre
Organisation - how different are the resources, provider expertise
and the organisation of care delivery in the intervention arm of the
trial and those available in usual care?
4 We will use usual staff and resources, but some extra resources will
be necessary to hire researchers for the study. Visits will be conducted
at the usual care facilities in each centre
Flexibility (delivery) - how different is the flexibility in how the
intervention is delivered and the flexibility likely in usual care?
5 The intervention is flexible, similar to usual care
Flexibility (adherence) - how different is the flexibility in how
participants must adhere to the intervention and the flexibility likely
in usual care?
4 No extra measures. Participants will be free to partake in the
intervention or drop it, but drugs will be prescribed and given to the
participants during visits. This is different from usual care (patients
have a prescription and go to the pharmacy to buy drugs)
Follow up - how different is the intensity of measurement and follow
up of participants in the trial and the likely follow up in usual care?
4 The primary outcome will be assessed after 1, 3 and 6months, as it is
usually in everyday practice. Six months represent a clinically sound
time frame for assessing the overall tolerability of medications,
including both acute, short-term and medium-to-long-term effects.
Visits could be slightly longer than usual to assess all the scales and
long-term effects and adverse events could occur after 6 months
Primary outcome - to what extent is the trial’s primary outcome
relevant to participants?
5 Primary outcome is relevant to participants and policy makers
Primary analysis - to what extent are all data included in the
analysis of the primary outcome?
5 The intention-to-treat (ITT) population will consist of all randomized par-
ticipants. This ITT population will be used for the analysis of both pri-
mary and secondary outcomes. Missing values in rating scales will be
imputed using the last observation carried forward (LOCF) approach
The Pragmatic–Explanatory Continuum Indicator Summary-2 (PRECIS 5)-point Likert scale score: (1) very explanatory; (2) rather explanatory; (3) equally pragmatic/
explanatory; (4) rather pragmatic; (5) very pragmatic
DSM-5 the Diagnostic and statistical manual of mental disorders, 5th edition
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Such criteria will select participants similar to those who
require antidepressant treatment under usual care, includ-
ing patients with multiple medical comorbidities. The
recruitment will be pragmatic, as participants will be
consecutively enrolled among those attending inpatient
and outpatient community services and fulfilling the study
inclusion criteria. People with new-onset or pre-existing
major depression will be eligible. Therefore, people who
are not on antidepressant treatment at baseline and those
who are already in treatment but needing a switch of
medication on clinical grounds, will be eligible. There will
not be any overt recruitment effort, as that could lead to
the recruitment of participants who do not resemble usual
care. Also, allowing different recruitment settings, having
multiple sites of recruitment and selecting patients similar
to those who are treated in every day clinical practice, will
increase the generalizability of trial results. Randomization
will be stratified by centre to control for potential risk of
excessive heterogeneity between centres. All recruiters will
take part in training meetings on recruitment procedures,
including timing, how to administer rating scales and how
to provide short synthetic yet exhaustive information to
the patients. This is intended to minimize heterogeneous
recruiting practices in different centres, which might
reflect different characteristics of the patients recruited.
We will keep track of the number of patients invited who
refuse to participate. According to these features, the
PRECIS-2 “setting” domain has been evaluated as
pragmatic.
Interventions
Participants will be randomized to either vortioxetine
or one of the SSRIs. Doctors will be free to choose
which SSRI is more appropriate among those mar-
keted in Italy and commonly used in clinical practice
in older people (sertraline, citalopram, escitalopram,
paroxetine, fluoxetine, fluvoxamine). A flexible dosing
schedule, within the licensed dose range and in line
with the summary of product characteristics (SPC),
will be suggested (Table 2) in order to resemble
clinical practice as much as possible. All medications
will be prescribed and switched accordingly to current
guidelines.
Clinicians and participants will choose the drug
formulation (tablets versus drops) following everyday
practice, and no measures will be implemented to opti-
mise treatment adherence. According to the PRECIS-2
“flexibility-delivery” and “flexibility-adherence” domains,
treatment delivery has been rated as pragmatic, although
a full score of 5 could not be reached as we were
formally required to follow the EU pharmacovigilance
regulation [39, 40].
Outcomes
The number of participants withdrawing from allocated
treatment due to adverse events at the end of the study (6
months) will represent the primary outcome. This meas-
ure may be considered a pragmatic proxy of tolerability
[41] as it occurs when adverse events actually reach an un-
bearable burden, as perceived by patients and/or relatives
and/or carers and/or clinicians. Antidepressant treatment
will be considered withdrawn due to adverse effects when
the drug is stopped for more than two consecutive weeks
following the occurrence of any adverse event, based on
clinical judgement and/or as reported by participants.
Participants will also be evaluated after 1, 3 and 6 months
from randomization, collecting relevant clinical informa-
tion and assessing scales, as shown in Table 3. The
information on the primary outcome and on any co-
medication taken by the participant will be collected using
a predefined follow-up form. Side effects responsible for
treatment withdrawal, and their severity, will be recorded
on the follow-up form and an ad hoc form for severe
adverse events (SAEs).
Secondary outcomes were chosen taking into account
particular clinical characteristics of depression in older
Table 2 Treatments and dosing schedule
Medication Licensed dose range in
the elderly
Notes from the registered summary of product characteristics
Vortioxetine 5–20 mg/day The minimum effective dose of 5 mg vortioxetine once daily should always be used as an initial dose for
participants aged ≥ 65 years. Caution should be exerted when prescribing to elderly participants at doses
> 10mg vortioxetine once daily
Sertraline 50–200mg/day Caution is required in the elderly, because these patients may be at greater risk of hyponatraemia
Paroxetine 20–40mg/day In the elderly, increased plasma concentrations of paroxetine have been reported, however, within the
range observed in younger patients. The treatment should start at the same doses used in adults
Citalopram 10–20mg/day In the elderly, half of the dose range prescribed in adults is required
Escitalopram 5–10 mg/day In the elderly, half of the dose range prescribed in adults is required
Fluoxetine 20–60mg/day Caution is required when the dose is increased in the elderly, and generally the daily dose should not be
above 40 mg/day. The maximum recommended dose is 60 mg/day
Fluvoxamine 100–300mg/day In elderly participants, titration should be slower and the dosage should always be established with caution
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people (i.e. higher risk of committing suicide and higher
likelihood of comorbid medical conditions) [42, 43] and
the specific peculiar characteristics of vortioxetine (i.e.
potential pro-cognitive effects) [23].
Secondary outcomes will include:
1. Acceptability: withdrawals from allocated treatment
due to any cause (this outcome measure will
include withdrawals due to side effects plus
withdrawals for any other issues). Acceptability is
generally considered a pragmatic measure of the
balance between efficacy and tolerability of
treatments [44];
2. Overall mortality;
3. Any episode of deliberate self-harm;
4. Suicide mortality;
5. Adverse events, measured as the mean change in
scores on the Antidepressant Side-Effect Checklist
(ASEC) [45] at each time point. ASEC is a validated
rating scale measuring the occurrence and severity
of 21 antidepressant adverse events;
6. Response to treatment, defined as a reduction of at
least 50% in the baseline score of the Montgomery–
Åsberg Depression Rating Scale (MADRS) [46, 47]
at each time point. MADRS is a validated, 10-item
questionnaire for assessing the severity of depres-
sion. Usually, scores of 0–6 indicate absence of
depression, 7–9 mild depression, 20–34 moderate
depression and > 34 severe depression. This rating
scale is a reliable tool for assessing depression in
elderly patients [48];
7. Efficacy, measured as mean change scores on the
MADRS at each time point;
8. Quality of life, measured as mean change scores on
the self-administered scale the Euroqol 5
Dimensions (EQ-5D) [49], at each time point. The
EQ-5D explores 5 areas, including mobility, self-
care, usual activities, pain/discomfort and anxiety/
depression, and assesses the overall subjective per-
ception of health on an analog scale. The EQ-5D is
a reliable tool for assessing quality of life in older
people [50];
9. Cognitive performance, measured as mean change
scores on the Short Blessed Test (SBT) [51] at each
time point. The SBT is a validated, six-item
weighted instrument, originally designed to identify
dementia, which assesses orientation, registration
and attention.
Rating scales to assess the secondary outcomes will be
administered by assessors blinded to treatment alloca-
tion, at 1, 3 and 6 months after randomization. In
addition, the Charlson Age-Comorbidity Index (CACI)
[52] will be employed. This is a validated rating scale
used to evaluate the degree of medical comorbidity and
predict 10-year survival in participants with multiple
comorbidities. All study tools and phases are shown in
Table 3.
Safety
The VESPA study will operatively employ the definitions
endorsed by the EC Directive 2001/20/EC [53]. As soon as
a severe adverse event occurs, an ad hoc form for SAEs
will be completed and forwarded to the coordinating
centre (University of Verona), in accordance with the EU
regulation about pharmacovigilance in clinical research
[39]. If for any reason the disadvantages of participation
appear to be significantly greater than foreseen, the
Principal Investigator (CB) of the site will inform trial
participants and the bodies providing ethical oversight.
Table 3 Study timeline and tools









Review of criteria for inclusion in the study X
Informed consent document signed X
Randomization (allocation to treatment and number assigned) X
Recruitment form X
ASEC X X X
MADRS X X X X
EQ-5D X X X X
CACI X X X X
SBT X X X X
Follow-up form X X X
Severe adverse event (SAE) form ←← any time →→
ASEC Antidepressant Side-Effect Checklist, MADRS Montgomery–Åsberg Depression Rating Scale, EQ-5D Euroqol 5 Dimensions, CACI Charlson Age-Comorbidity
Index, SBT Short Blessed Test
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Considering that the study medications are already in
the Italian market, and considering that they will be pre-
scribed for licensed indications without altering clinical
practice, the VESPA study has not appointed an ad hoc
data safety and monitoring committee.
Randomization and assignment of interventions
Participants will be randomly assigned to vortioxetine
or SSRIs in an allocation ratio of 1:1. A centralized
web-based randomization procedure will be employed
to guarantee the concealment of allocation. The trial
biostatistician will prepare the sequence of treatments
randomly permuted in blocks of constant size. The
site investigators will not know the block size. Alloca-
tion will be stratified by recruiting centre. By using
the web-based application RedCap [54], investigators
will be able to screen participants for inclusion,
administer instruments maintaining blinding to treat-
ment allocation and randomize the participants.
Data collection and management
At baseline, before randomization, and after 1, 3 and 6
months, socio-demographic and clinical information will
be collected along with the administration of the afore-
mentioned validated rating scales (the MADRS, EQ-5D,
CACI, SBT and ASEC). Data on the use of other medi-
cations will be registered at every visit. The ASEC scale
will be administered only during follow up.
All study data will be collected with RedCap and
digitally stored by the Istituto di Ricerche Farmacolo-
giche Mario Negri IRCCS, a not-for-profit biomedical
research organization based in Milan (Italy), where
the statistical analysis will also be performed. RedCap
will allow immediate data validation at the time of
data collection. Moreover, a set of electronic and
manual edit checks will be performed. The local co-
ordinator of each recruiting centre will store and
safely preserve hard-copy documents (signed informed
consent and self-administered questionnaires) for at
least 7 years after the end of the study, according to
the Italian law. At the end of the study the full data-
set will be made available upon motivated request, as
a spreadsheet file in an online repository (e.g. Dryad
Digital Repository). This is in line with findable,
accessible, interoperable and reusable (FAIR) princi-
ples [55], aimed at enhancing the accessibility and
reutilization of novel research data.
The accuracy and completeness of data collection will
be monitored by site visits. At least one visit for each
recruiting centre is planned. Furthermore, auditing will
also be carried out remotely, as the data manager of the
study will be able to regularly check the trial dataset
through the web application RedCap.
Sample size
Based on differences in the withdrawal rate due to ad-
verse events among patients receiving SSRIs or vortioxe-
tine, as identified in a meta-analysis of the use of
antidepressants in older people [13] and in three clinical
trials of vortioxetine in older patients with depression
[26, 32, 56], we expect the vortioxetine group to have a
clinically significant advantage, with a reduction in the
withdrawal rate from about 17% [13] to about 5% [26,
32, 56]. A sample size of 276 participants (138 in each
group) achieves 90% power to detect a difference of 12%
between the two proportions of patients who withdraw,
in favour of vortioxetine. The test statistics will be the
two-sided Z test with pooled variance. The significance
level of the test is targeted at 5%. On the basis of the
aforementioned studies, we can assume that about 23%
of the participants could withdraw within 6 months (the
mean of the total dropout rates in vortioxetine and SSRI
studies in older people). Therefore 358 participants (179
in each group) will be enrolled in order to obtain at least
276 evaluable participants. The sample size calculation
was performed according to the methodology described
by Pocock [57].
Statistical analysis
According to the pragmatic principle of intention to
treat (ITT), efforts will be made to follow each partici-
pant until the end of the study. The ITT population will
consist of all randomized participants, and will be used
for the analysis of both primary and secondary out-
comes. The absolute risk of the primary outcome will be
calculated in the ITT population. Participants with miss-
ing primary outcome data will be allocated to the worst
outcome. When possible, in addition to the primary ana-
lysis, appropriate statistical methods will adjust for the
potential confounding effect of prognostic factors (sex,
age, living condition, severity of comorbid medical con-
ditions, previous psychiatric history, MADRS score at
baseline). Missing rating scale scores will be imputed
using the last observation carried forward (LOCF) ap-
proach: ratings will be carried forward from the last
available assessment to the 6-month follow-up assess-
ment. As a secondary analysis, missing scores will be
imputed following a multiple imputation approach [58].
In order to check the results of the ITT approach,
though for confirmatory purposes only, the primary out-
come will also be analysed using a per-protocol (PP) ap-
proach. According to the PP approach, analysis will be
restricted to participants with primary outcome assess-
ment available at 6 months. Participants withdrawing for
reasons not related to adverse effects will be excluded
from the analysis.
The proportion of participants withdrawing from the
study due to adverse events within 6 months of follow
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up will be compared between the two groups of treat-
ment using a logistic regression with centre (random
variable) as a covariate. A multivariable analysis (second-
ary analysis) will be performed through a Poisson regres-
sion model with robust error variance, given that this
procedure allows direct estimation of relative risk [59].
For dichotomous secondary outcomes, the proportion
of participants who withdraw from the study within 6
months due to adverse events will be compared between
the two groups of treatment using logistic regression
with centre (random variable) as a covariate. When pos-
sible, a multivariable analysis will be performed through
a Poisson regression model with robust error variance.
For continuous secondary outcomes, the 6-month esti-
mate will be compared between the two treatment
groups using analysis of covariance with baseline value
as an additional covariate, or using the Mann-Whitney
test on the data on changes, according to the distribu-
tion of the variable. The same outcomes will be studied
using linear mixed models, taking into account all as-
sessments to evaluate the rate of change with shorter re-
peated evaluations and no need for imputation of
missing values. Further, score changes on the subscales
will be evaluated in order to detect possible specific
treatment-related side effects.
A Cox proportional hazard model will be used to ex-
plore time to treatment withdrawal due to adverse
events (secondary analysis). The proportional hazard as-
sumption of the effects will be tested. A Cox propor-
tional hazards model was chosen as it is a regression
model commonly used for investigating the association
between the survival time of patients (who drop out due
to side effects) and one or more predictor variables (allo-
cation to vortioxetine or control SSRI).
Adverse events will be tabulated. The nominal value
for statistical significance will be set at 0.05, two-tailed.
A specific statistical analysis protocol will be produced
and made publicly available before the inclusion of the
last participant. All analyses will be performed using
STATA [60], release 15 or higher.
Ethics and dissemination
This study will be conducted according to globally ac-
cepted standards of good clinical practice, as defined in
the ICH E6 Guideline for Good Clinical Practice, 1 May
1996, in agreement with the Declaration of Helsinki [61]
and in keeping with local regulations. The recruiting in-
vestigators will obtain informed consent. All participants
will be informed about the study procedures and aims,
both verbally and by written documentation. The sub-
ject’s consent will be confirmed by the personally dated
signature of the participant and by the personally dated
signature of the person conducting the informed consent
discussion. Participants can withdraw from the study at
any time without further explanation or any negative
consequences. Participants’ data will be managed and
safeguarded in accordance with the European Data Pro-
tection Regulation 2016/679 [62]. The highly pragmatic
design will minimize the time deduction to ordinary
clinical practice. An Ethics Advisory Board (EAB) will
indirectly supervise the process of recruitment, informed
consent procedures and data management (protection
and privacy), taking into due account the vulnerability of
the population. Once the final report is available, the
study results will be extensively disseminated to the
international scientific community in the form of peer-
reviewed journal articles, giving preference to open-
access journals.
The study is financially supported by the AIFA and
has been approved by the Ethics Committee for Clinical
Research of Verona and Rovigo (Comitato Etico per la
Sperimentazione Clinica delle Province di Verona e
Rovigo) (prot. n. 61,211 of the 19/09/2018; Protocol ver-
sion n. 1.5 of the 09/06/2018).
Discussion
This study is designed to achieve a high level of pragma-
tism. This approach will allow us to minimize the risk of
selection bias (particularly relevant when assessing frail
populations such as older people, who are often ex-
cluded from experimental research), to resemble routine
clinical procedures as much as possible and therefore to
maximize the external validity and generalizability of the
results [34]. First, participants will be enrolled on the
basis of the need for an antidepressant prescription be-
cause of a depressive episode. Although the diagnostic
reference standard is represented by DSM-5 criteria, in
line with routine clinical practice, no formal diagnostic
assessment will be performed, in order to recruit pa-
tients as similar as possible to those treated in the real
world. No limitations to the recruitment setting will be
applied. Rating scales will be easy to administer and of
relatively short duration, in order not to substantially
alter clinical practice. Second, a web-based application
will allow us to simplify the process of recruitment,
randomization and collection of socio-demographic and
clinical data, minimizing the time deducted from ordin-
ary clinical practice. Third, the comparison group will
consist of participants receiving any of the available
SSRIs. We made this choice in order to avoid the possi-
bility of selection bias, that is to avoid the systematic ex-
clusion of participants who did not benefit from a
specific SSRI in the past. Furthermore, a flexible dosing
schedule will be employed, according to clinical judge-
ment, within the recommended therapeutic range.
Some limitations need to be outlined. First, according
to the current pharmacovigilance regulation of the
European Union, medication boxes must be labelled and
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dispensed by the hospital pharmacy. This deviates from
ordinary practice and may have an impact on adherence
to medications, since participants will not have to go
and buy medications at their local pharmacies, but the
medications needed until the next visit will be distrib-
uted to them after each visit. Second, in order to avoid
the potential confounding effect of other psychotropic
drugs, to be included in the trial patients have to discon-
tinue any other antidepressant or second generation
antipsychotic before random allocation, but after ran-
dom allocation any concomitant medication will be
allowed. Again, the aim of this is to reflect everyday
practice, as older patients are sometimes prescribed low
doses of second-generation antipsychotics or antidepres-
sants (e.g. mirtazapine, amitriptyline, trazodone) for
treatment of insomnia or for other symptoms (e.g. cach-
exia, cephalalgia, etc.).
Third, the open-label design might be associated with
a risk of performance bias. Theoretically, it may be pos-
sible that clinicians, being aware of the treatments re-
ceived by participants, perform differently in the
allocated treatment arms, based on personal subjective
judgements. For example, they may provide vortioxetine
or the control SSRI at excessively low or high doses, al-
tering the likelihood of participants dropping out of
treatment because of side effects or lack of efficacy. Al-
though we cannot completely rule out this possibility,
we note the following. First, as both treatment arms in-
volve active antidepressants, it seems unlikely that
doctors involved in the study, working in very diverse
settings across Italy, share similar a priori opinions and,
based on these opinions, systematically favour or
disfavour either vortioxetine or the control SSRIs.
Second, information on any dose changes, use of con-
comitant medicines and provision of additional non-
pharmacological treatments will be recorded, which is
important to investigate if the two groups were treated
similarly, apart from the study medications. Third,
blinded assessors will independently assess the presence
and severity of adverse events using the ASEC, and this
will allow an internal quality check of the accuracy of
the primary outcome.
Considering the overall psychological, medical and
economic burden of depression in older people, and the
few available pharmacological alternatives for treating
them, the results of this study are likely to have a posi-
tive impact on everyday clinical practice. Furthermore,
considering the pragmatic nature of the study, we expect
that results will be immediately applicable to ordinary
practice without requiring any specific training or imple-
mentation strategies. If the hypothesis of better tolerabil-
ity of vortioxetine is confirmed, this drug may become a
reference first-line drug for the treatment of depression
in older people. This, besides improving the overall
psychological well-being and quality of life in older
people with depression, might at the same time reduce
hospitalizations for medical adverse events (such as falls,
bleeding, hyponatraemia, QTc alterations), poor medical
outcomes and related healthcare costs. If, on the other
hand, vortioxetine is not better-tolerated than SSRIs, its
place in the treatment of older people will be clearer,
and the VESPA study results will be used to better
inform clinical and policy practice.
Additionally, this study may have regulatory implica-
tions, considering that currently according to the EMA,
“caution is advised when treating participants ≥ 65 years
of age with doses higher than 10 mg vortioxetine once
daily for which data are limited” [19, 21]. We expect that
this statement may be reformulated in view of the study
results: if vortioxetine is better-tolerated than the SSRIs,
by mentioning its favourable tolerability profile; if
vortioxetine is less well-tolerated than the SSRIs, by
further reinforcing the cautionary statement.
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